Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Whitfield

Showing results (261-270 of 269) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 269 results.
Annals of the Rheumatic Diseases|December 11, 2025
RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosisRezvan Parvizi, Zhiyun Gong, Helen C Jarnagin, et al.
The Journal of Investigative Dermatology|January 28, 2023
CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in FibroblastsJillian M Richmond, Dhrumil Patel, Tomoya Watanabe, et al.
Nature Genetics|June 7, 2011
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promotersTiffany Hung, Yulei Wang, Michael F Lin, et al.
Nature Reviews. Rheumatology|March 3, 2025
Publisher Correction: An international perspective on the future of systemic sclerosis researchDavid J Abraham, Carol M Black, Christopher P Denton, et al.
The Journal of Investigative Dermatology|November 29, 2017
Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic SclerosisTobias C Messemaker, Loubna Chadli, Guoshuai Cai, et al.
Nature Reviews. Rheumatology|February 14, 2025
An international perspective on the future of systemic sclerosis researchDavid J Abraham, Carol M Black, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|November 27, 2019
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profileBrian Skaug, Dinesh Khanna, William R Swindell, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Pageof 27

Showing results (261-270 of 269) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 269 results.
Annals of the Rheumatic Diseases|December 11, 2025
RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosisRezvan Parvizi, Zhiyun Gong, Helen C Jarnagin, et al.
The Journal of Investigative Dermatology|January 28, 2023
CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in FibroblastsJillian M Richmond, Dhrumil Patel, Tomoya Watanabe, et al.
Nature Genetics|June 7, 2011
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promotersTiffany Hung, Yulei Wang, Michael F Lin, et al.
Nature Reviews. Rheumatology|March 3, 2025
Publisher Correction: An international perspective on the future of systemic sclerosis researchDavid J Abraham, Carol M Black, Christopher P Denton, et al.
The Journal of Investigative Dermatology|November 29, 2017
Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic SclerosisTobias C Messemaker, Loubna Chadli, Guoshuai Cai, et al.
Nature Reviews. Rheumatology|February 14, 2025
An international perspective on the future of systemic sclerosis researchDavid J Abraham, Carol M Black, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|November 27, 2019
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profileBrian Skaug, Dinesh Khanna, William R Swindell, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Pageof 27